Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Unmet needs in high-risk MDS and ongoing trials in the field

Thomas Cluzeau • 12 Jun 2022
EHA 2022
Myelodysplastic Syndromes Antibodies Azacitidine Magrolimab Sabatolimab Venetoclax
ENHANCE STIMULUS-MDS1 STIMULUS-MDS2 VERONA

Thomas Cluzeau, MD, PhD, Central University Hospital of Nice, Nice, France, highlights some unmet needs in high-risk myelodysplastic syndromes (HR-MDS), drawing focus on the need to improve treatment combinations with azacitidine and ongoing trials evaluating these combinations. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Thomas Cluzeau

1:40
Highlights in LR-MDS at the ASH 2023 meeting
Thomas Cluzeau • 9 Dec 2023
1:55
Long-term real-world experience of CPX-351 in patients with t-AML and MRC-AML
Thomas Cluzeau • 9 Dec 2023
2:17
VENTOGRAFT trial: AZA, VEN, and DLI in patients with MDS and AML who have relapsed following alloSCT
Thomas Cluzeau • 10 Dec 2023
Novel targets, combinations & treatments
Eunice Wang et al. • 4 Sep 2023

Related Videos

2:22
Haplo-SCT for older patients with AML/MDS, and should age be a barrier to transplantation?
Raynier Devillier • 15 Apr 2024
2:31
Emerging treatment options for patients with ESA-refractory MDS: luspatercept & imetelstat
Eva Hellström-Lindberg • 11 Apr 2024
1:49
The unmet needs of patients with VEXAS syndrome
Maël Heiblig • 17 Apr 2024
1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
The content of VJHemOnc is intended for healthcare professionals